

OFFICIALLY LICENSED
BEST OF ASCO®
2022 ANNUAL MEETING



THE 17th BEST OF ASCO₂₂ VIRTUAL

July 7 - 8, 2022 | Virtual Meeting

Organized by AUBMC
Licensed by ASCO
In collaboration with LSMO, EOS and AMAAC



Best of ASCO 2022 Lebanon

July 7-8, 2022

Organized by the American University of Beirut Medical Center (AUBMC)

Licensed by the American Society of Clinical Oncology (ASCO)

In collaboration with the Lebanese Society of Medical Oncology (LSMO), Emirates Oncology Society (EOS) and the Arab Medical Association Against Cancer (AMAAC)

PLANNING COMMITTEE:

Nagi S. El Saghir, MD (Chair) - Arafat Tfayli, MD - Hiba Moukadem, MD - Roger Khater, MD - Sami Khatib, MD

INTERNATIONAL & REGIONAL FACULTY:

Ahmad Awada, MD (Belgium)

Eileen O'Reilly, MD (USA)

Etienne Brain, MD (France)

Ghassan Abou Alfa, MD (USA)

Hamdy A. Azim, MD (Egypt)

Hassan Jaafar, MD (UAE)

Hikmat Abdel Razek, MD (Jordan)

Humaid Al Shamsi, MD (UAE)

Hussein Tawbi, MD (UAE)

Ibrahim Abou Ghaida, MD (UAE)

Iman Dika, MD (USA)

Jennifer Bellon, MD (USA)

Mohamad Mohty, MD (France)

Nabil Adra, MD (USA)

Omalkhair Abulkhair, MD (UAE)

Philip Philip, MD (USA)

Raya Saab, MD (USA)

Sanaa Sukhun, MD (Jordan)

Toni Choureiri, MD (USA)

Best of ASCO 2022 Lebanon

July 7-8, 2022

LEBANESE FACULTY

Abir Ahmadieh, MD

Ahmad Ibrahim, MD

Ahmad Younes, MD

Ali Bazarbachi, MD

Ali Shamseddine, MD

Arafat Tfayli, MD

Bassem Youssef, MD

Fadi Karak, MD

Fadlo Khuri, MD

Hady Ghanem , MD

Hampig Kourie, MD

Hazem Assi, MD

Hiba Moukadem, MD

Iman Abou Dalle, MD

Jean El Cheikh, MD

Joseph Kattan, MD

Joseph Makdessi, MD

Khaled Ibrahim, MD

Marwan Ghosn, MD

Marwan Najjar, MD

Miguel Abboud, MD

Muhieddine Seoud, MD

Nagi El Saghir, MD

Nour Moukalled, MD

Peter Noun, MD

Reem Abdallah, MD

Toufic Eid, MD

Thursday, July 7th, 2022

10:00 - 10:15 Opening Welcome Notes:
Nagi S. El Saghir, MD, AUBMC, Best of ASCO22 Lebanon
Roger Khater, MD, President LSMO
Sami Khatib, MD, President AMAAC

10:15 - 11:00 Hematologic Malignancies | Lymphoma and Chronic Lymphocytic Leukemia

Chairpersons: Issam Chehade, MD - Sami Khatib, MD

Speakers: Jean El Cheikh, MD - Ali Bazarbachi, MD - Iman Abou Dalle, MD - Ahmad Ibrahim, MD

10:15 - 10:25 Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL)
[Abstract LBA7502](#), Michael L. Wang, MD | **Presented by Jean El Cheikh, MD**

10:25 - 10:35 First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
[Abstract 7503](#), Stephen M. Ansell, MD | **Presented by Ali Bazarbachi, MD**

10:35 - 10:45 Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study
[Abstract 7519](#), William G. Wierda, MD, PhD | **Presented by Iman Abou Dalle, MD**

10:45 - 10:55 Sub-cutaneous rituximab induction followed by short rituximab maintenance improves progression-free survival in patients with low-tumor burden follicular lymphoma: Final Results of FLIRT Phase III Trial, a LYSA Study
[Abstract 7512](#), Guillaume Cartron, MD | **Presented by Ahmad Ibrahim, MD**

10:55 - 11:00 Q&A

Thursday, July 7th, 2022

11:00 - 11:45 Hematologic Malignancies | Plasma Cell Dyscrasia

Chairpersons: Hanane Yassine, MD - Colette Hanna, MD

Speakers: Nour Moukalled, MD - Khaled Ibrahim, MD - Mohamad Mohty, MD

- 11:00 - 11:10 Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. [Abstract LBA4](#), Paul G. Richardson, MD | **Presented by Nour Moukalled, MD**
- 11:10 - 11:20 ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma [Abstract 8001](#), Dominik Dytfeld, MD | **Presented by Khaled Ibrahim, MD**
- 11:20 - 11:30 Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post LPI. [Abstract 8028](#), Saad Z Usman, MD | **Presented by Mohamad Mohty, MD**
- 11:30 - 11:40 Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1. [Abstract 8033](#), Ajay K Nooka, MD | **Presented by Mohamad Mohty, MD**
- 11:40 - 11:45 Q&A

11:45 - 12:10 Pediatric Oncology

Chairpersons: Nada Sbeity, MD - Samar Mouwakkat, MD

Speakers: Miguel Abboud, MD - Peter Noun, MD

- 11:45 - 11:55 Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL) [Abstract 10000](#) Norris, Robin E, MD | **Presented by Miguel Abboud, MD**
- 11:55 - 12:05 Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study [Abstract 10001](#), Laura E. Hogan, MD | **Presented by Peter Noun, MD**
- 12:05 - 12:10 Q&A

12:10 - 12:25

Coffee Break

Thursday, July 7th, 2022

12:25 - 13:00 Gynecologic Cancer + Sarcoma

Chairpersons: Nadine Kassis, MD - Oussama Safar, MD

Speakers: Reem Abdallah, MD - Muhieddine Seoud, MD - Hampig Kourie, MD

12:25 - 12:35 ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer.

[Abstract LBA5500](#) Bradley J. Monk, MD | **Presented by Reem Abdallah, MD**

12:35 - 12:45 Mirvetuximab sorvatansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha: FRa expression: characterization of antitumor activity in the SORAYA study. [Abstract 5512](#), Ursula A. Matulonis, MD | **Presented by Muhieddine Seoud, MD**

12:45 - 12:55 Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study. [Abstract 5509](#), Ana Oaknin, MD | **Presented by Hampig Kourie, MD**

12:55 - 13:00 Q&A

13:00 - 13:30 Non-CME non-Best of ASCO non-CME Satellite Symposium by Roche

Updates in the treatment of HER2+ Early Breast Cancer | **Fadi Farhat, MD**

13:30 - 14:00 **Lunch Break**

Thursday, July 7th, 2022

14:00 - 14:50 Central Nervous System Tumors & Sarcoma

Chairpersons: Hussein Darwish, MD - Georges Hachem, MD - Haifa Dbouk, MD

Speakers: Toufic Eid, MD - Hazem Assi, MD - Marwan Najjar, MD - Raya Saab, MD

- 14:00 - 14:10 Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. [Abstract 2000](#), Jonathan T. Yang, MD, PhD | **Presented by Toufic Eid, MD**
- 14:10 - 14:20 Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102). [Abstract 2001](#), Jann N. Sarkaria, MD | **Presented by Hazem Assi, MD**
- 14:20 - 14:30 Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group. [Abstract 2003](#), Philipp Karschnia, MD | **Presented by Marwan Najjar, MD**
- 14:30 - 14:40 Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). [Abstract LBA2](#), Martin G McCabe, MD | **Presented by Raya Saab, MD**
- 14:40 - 14:50 Q&A

Thursday, July 7th, 2022

14:50 - 15:25 Symptoms and Survivorship / Health Services Research and Quality Improvement

Chairpersons: Rana Yamout, MD - Adda Bounedjar, MD

Speakers: Hassan Ghazal, MD - Hady Ghanem, MD - Hiba Moukadem, MD

14:50 - 15:00 Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.

Abstract 12000, Antoine ITALIANO, MD, PhD | Presented by Hassan Ghazal, MD

15:00 - 15:10 Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221.

Abstract 12023, Ciao-Sin Chen, MD | Presented by Hady Ghanem, MD

15:10 - 15:20 Oral minoxidil for the treatment of late alopecia in cancer survivors.

Abstract 12022, Alyce M. Kuo, MD | Presented by Hiba Moukadem, MD

15:20 - 15:25 Q&A

15:25 - 15:35 Break

15:35 - 16:10 Genitourinary Cancer - Kidney and Bladder

Chairpersons: Albert Hajj, MD - Georges Chahine, MD

Speakers: Toni Choueiri, MD

15:35 - 15:45 EVEREST: EVERolimus for Renal cancer Ensuing Surgical Therapy, A phase III study | Toni Choueiri, MD

15:45 - 15:55 The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214. Abstract 4502, David Cella, MD | Presented by Toni Choueiri, MD

15:55 - 16:05 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426. Abstract 4502, David Cella, MD | Presented by Toni Choueiri, MD

16:05 - 16:10 Q&A

Thursday, July 7th, 2022

16:10 - 16:50 Genitourinary Cancer - Prostate, Testicular, and Penile

Chairpersons: Deborah Mukherji, MD - Mohamad Bulbul, MD

Speakers: Joseph Makdessi, MD - Joseph Kattan, MD - Nabil Adra, MD

16:10 - 16:20 Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

[Abstract LBA5004](#), Ian D Davis, MD | **Presented by Joseph Makdessi, MD**

16:20 - 16:30 TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival after median follow-up of 3 years (ANZUP 1603).

[Abstract 5000](#), Hofman Michael, MD | **Presented by Joseph Kattan, MD**

16:30 - 16:40 Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management.

[Abstract 5007](#), Hong Truong, MD | **Presented by Nabil Adra, MD**

16:40 - 16:50 Q&A

Friday July 8, 2022

10:00 - 10:35 Head and Neck Cancer

Chairpersons: Ghazi Nsouli, MD - Marc Mourad, MD

Speakers: Fadlo Khuri, MD - Bassem Youssef, MD

- 10:00 - 10:10 Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
[Abstract 6077](#), Raneeh Mehra, MD | **Presented by Fadlo Khuri, MD**
- 10:10 - 10:20 An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
[Abstract 6004](#), ATUL Sharma, MD | **Presented by Fadlo Khuri, MD**
- 10:20 - 10:30 Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised phase III trial.
[Abstract 6000](#), Jun Ma, MD | **Presented by Bassem Youssef, MD**
- 10:30 - 10:35 Q&A

Friday, July 8th, 2022

10:35 - 11:25 Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Chairpersons: Roger Khater, MD - Sami Khatib, MD

Speakers: Ibrahim Abou Ghaida, MD - Marwan Ghosn, MD - Hassan Jaafar, MD - Arafat Tfayli, MD

10:35 - 10:45 Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).

[Abstract 8504](#), Apar Kishor Ganti, MD | **Presented by Ibrahim Abou Ghaida, MD**

10:45 - 10:55 SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

[Abstract LBA8507](#), Charles M. Rudin, MD | **Presented by Marwan Ghosn, MD**

10:55 - 11:05 Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.

[Abstract 8500](#), Fuming Qiu, MD | **Presented by Hassan Jaafar, MD**

11:05 - 11:15 EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.

[Abstract 8512](#), M. O'Brien, MD | **Presented by Arafat Tfayli, MD**

11:15 - 11:25 Q&A

Friday, July 8th, 2022

11:25 - 12:15 Lung Cancer - Non-small Cell Metastatic

Chairpersons: Ghazi Nsouli, MD - Roger Khater, MD

Speakers: Arafat Tfayli, MD - Fadi Karak, MD - Humaid Al Shamsi, MD - Ahmad Younes, MD

- 11:25 - 11:35 Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score $\geq 50\%$: FDA pooled analysis.
[Abstract 9000](#), [Oladimeji Akinboro, MD](#) | **Presented by Arafat Tfayli, MD**
- 11:35 - 11:45 KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation [Abstract 9002](#), [Alexander I. Spira, MD](#) | **Presented by Fadi Karak, MD**
- 11:45 - 11:55 Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-study S1800A.
[Abstract 9004](#), [Karen L. Reckamp, MD](#) | **Presented by Humaid Al Shamsi, MD**
- 11:55 - 12:05 Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreak100.
[Abstract 102](#), [Bob T. Li, MD, PhD](#) | **Presented by Ahmad Younes, MD**
- 12:05 - 12:15 Q&A
- 12:15 - 12:45 Non-CME non-Best of ASCO Satellite Symposium by Novartis
Updates on HR+ in advanced MBC from ASCO | **Ahmad Younes, MD**

12:45 - 13:15 Lunch Break

Friday, July 8th, 2022

13:15 - 13:45 Non-CME non-Best of ASCO Satellite Symposium by Roche
The Goal is cure - the role of Tecentriq in the management of early NSCLC patients | [Hazem Assi, MD](#)

13:45 - 14:35 **Gastrointestinal Cancer - Colorectal and Anal**

Chairpersons: Fadi Nasr, MD - Sally Tamraz, MD

Speakers: Ghassan Abou Alfa, MD - Ali Shamseddine, MD - Iman Dika, MD

13:45 - 13:55 Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial.

[Abstract LBA1](#), Takayuki Yoshino, MD | [Presented by Ghassan Abou Alfa, MD](#)

13:55 - 14:05 Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.

[Abstract LBA100](#), Jeanne Tie, MD | [Presented by Ghassan Abou Alfa, MD](#)

14:05 - 14:15 Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer

[Abstract LBA5](#), Andrea Cercek, MD | [Iman Dika, MD](#)

14:15 - 14:25 Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer.

[Abstract 3503](#), Antonio Avallone, MD | [Presented by Ali Shamseddine, MD](#)

14:25 - 14:35 Q&A

Friday, July 8th, 2022

14:35 - 15:15 Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary

Chairpersons: Aydah AlAwadhi, MD - Christina Khater, MD

Speakers: Eileen O'Reilly, MD - Philip Philip, MD

- 14:35 - 14:45 Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
[Abstract LBA4011](#), Shukui Qin, MD - Jin Li, MD | **Presented by Eileen O'Reilly, MD**
- 14:45 - 14:55 A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).
[Abstract 4004](#), Pamela L. Kunz, MD | **Presented by Philip Philip, MD**
- 14:55 - 15:05 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
[Abstract 4006](#), Akihiro Ohba, MD | **Presented by Eileen O'Reilly, MD**
- 15:05 - 15:15 Q&A

15:15 - 15:30 Break

Friday, July 8th, 2022

15:30 - 16:20 Breast Cancer - Metastatic

Chairpersons: Alaa Kandil, MD - Hesham Al Ghazali, MD - Meteb Al Foheidi, MD

Speakers: Nagi El Saghir, MD - Hamdy A. Azim, MD - Ahmad Awada, MD - Hikmat Abdel Razek, MD

- 15:30 - 15:40 Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04 , a randomized, phase 3 study .
[Abstract LBA3](#), Shanu Modi, MD | **Presented by Nagi El Saghir, MD**
- 15:40 - 15:50 Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician's Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
[Abstract LBA1001](#), Hope S. Rugo, MD | **Presented by Hamdy A. Azim, MD**
- 15:50 - 16:00 A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2 negative metastatic breast cancer (MBC): MAINTAIN trial.
[Abstract LBA1004](#), Kevin Kalinsky, MD | **Presented by Ahmad Awada, MD**
- 16:00 - 16:10 Fulvestrant plus capiwasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free survival data with enhanced biomarker analysis.
[Abstract 1005](#), RH Jones, FRCP, PhD | **Presented by Hikmat Abdel Razek, MD**
- 16:10 - 16:20 Q&A

Friday, July 8th, 2022

16:20 - 17:10 Breast Cancer - Local/Regional/Adjuvant

Chairpersons: Alaa Kandil, MD - Hassan Jaafar, MD - Zeina Ayoub, MD

Speakers: Etienne Brain, MD - Jennifer Bellon, MD - Omalkhair Abulkhair, MD - Sanaa Sukhun, MD

- 16:20 - 16:30 Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2-breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.
[Abstract](#) | **Presented by Etienne Brain, MD**
- 16:30 - 16:40 LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).
[Abstract LBA501, Timothy Whelan, MD](#) | **Presented by Jennifer Bellon, MD**
- 16:40 - 16:50 Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.
[Abstract 507, Michael Gnant, MD](#) | **Presented by Omalkhair Abulkhair, MD**
- 16:50 - 17:00 Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.
[Abstract 506, Kim, Hee Jeong, MD](#) | **Presented by Sanaa Sukhun, MD**
- 17:00 - 17:10 Q&A

Friday, July 8th, 2022

17:10 - 18:00 Melanoma/Skin Cancers and Developmental Therapeutics | Immunotherapy and Molecularly Targeted Agents and Tumor Biology

Chairpersons: Hazem Assi, MD - Marwan Ghosn, MD - Tarek Assi, MD

Speakers: Hussein Tawbi, MD - Ahmad Awada, MD - Abir Ahmadie, MD

- 17:10 - 17:20 Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study. [Abstract LBA9500](#), Georgina V. Long, MD | **Presented by Hussein Tawbi, MD**
- 17:20 - 17:30 Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047. [Abstract 9505](#) | **Presented by Hussein Tawbi, MD**
- 17:30 - 17:40 Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers. [Abstract 9507](#), Kara M. Schenk, MD | **Presented by Ahmad Awada, MD**
- 17:40 - 17:50 Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis
[Abstract 2507](#), Steven Blum, MD | **Presented by Abir Ahmadieh, MD**
- 17:50 - 18:00 Q&A

ADJOURN

SEE YOU in July 2023 at Best of ASCO 2023



Organized by:



LEBANON

4th Floor, Qubic Center
Daoud Ammoun Street
Horsh Tabet - Sin El Fil
P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Mobile: +961 71 103123

UAE

DMCC Business Centre
Almas Tower
Jumeirah Lakes
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +971 50 9110475

KUWAIT

Mezzanine floor,
Aliya Complex
Salem Al Mubarak St
Block 2, Salmiya - Kuwait
Tel: +965 6556 7669



infomed@infomedweb.com | www.infomedweb.com